Our science

Unraveling complex disease biology

Chronic diseases affect billions of people worldwide and account for the majority of global healthcare costs, yet their complex, multifactorial biology makes them the hardest conditions to diagnose and treat - resulting in major unmet medical needs.

We've reimagined how to analyze multiomic patient data. Our platform is the first to reveal the complex interplay of multiple genes and other heterogenous factors underpinning disease biology, to discover the specific causes of chronic diseases.

Our unique approach enables us to stratify disease populations at unprecedented resolution, accurately diagnose and triage patients and link individuals to effective treatments by the mechanisms of their disease.

World-leading precision medicine

People who have the same chronic disease diagnosis or symptoms may have different mechanistic causes and will therefore benefit from different interventions.

The mechanistic differences a too subtle to be found by any other analysis tools, including GWAS, AI/ML, polygenic risk scores (PRS) and knowledge graphs, which are inherently limited, lacking in patient context, and containing annotation biases.

At PrecisonLife, we go far beyond these methods, to find rich signal where others find none and explainable mechanistic insights to stratify patient populations from which more personalized decisions can be made.

Predictive disease models

With unique insights into the mechanisms driving complex diseases, we discover the biomarkers that reveal which individuals share that underlying biology.

This enables us to identify predictive risk signatures, uncover novel drug targets for specific patient subgroups, and enrich and de-risk clinical trials.

We help diagnose patients more accurately and, as new programs move into the clinic, match them to the treatments most likely to work - improving outcomes and reducing the cost of care.

An example is our Alzheimer’s disease study, which stratified an Alzheimer's patient population into six distinct subgroups, each with a different mechanistic etiology and high prevalence. Individuals in each group will respond to different therapies. Our mechanistic patient stratification biomarkers predict this response to optimize outcomes in drug discovery, clinical trials and healthcare. This level of stratification across complex diseases is unique to PrecisionLife.

Actionable insights reduced to clinical practice

Our biomarkers are rapidly reduced to practice in the form of mechanostics - first-in-class, low-cost and non-invasive genotypic precision medicine tests.

Mechanostic tests identify lifetime disease risk and the underlying mechanism of an individual's disease.

The results lead to earlier and more accurate disease diagnosis, personalized therapy selection, and clinical trials enriched with patients who will respond to the drug candidate being trialed.